AZACITIDINE IS THE PREPARATION OF CHOICE IN THE TREATMENT OF MYELODYSPLASTIC SYNDROMES PATIENTS

Aim. To compare the efficiency of the treatment of myelodysplastic syndrome (MDS) with azacitidine and cytarabine on the basis of the following criteria: overall survival (OS), toxicity, length of the hospitalization period, the life quality.

Methods. Research includes 36 patients with MDS aged from 42 up to 83. All patients were divided into two groups. The first group includes 15 patients aged from 55 up to 83. Basic therapy of the said patients involved usage of one of protocols, containing cytarabine “7+3” or “small doses of cytarabine” (“SDC”). The second group is represented by 21 patient aged from 42 up to 81. Treatment protocol of this group included azacitidine (Vaydaza) in a dose of 75mg/m² subcutaneouslywithin 7 days. Evaluation of treatment efficiency was held after 2, 4, 6 courses. The treatment was continued until symptoms of disease progression appeared.

Results. Including of azacitidine in treatment of MDS patients demonstrated the advantage in overall survival (38% vs 26.6%; р= 0.038), resulted in prolonged median survival (13.7 vs 7.9 months; р= 0.03). The frequency of the general response while using azacitidine in comparison to SDC constituted 76% vs 53%. The period of the disease until transformation to AML increased from 6.16 months to 10.6 months.

Conclusion.The including of azacitidine in the treatment of MDS patients improved the quality of life, decrease the dependence on blood transfusion, LOS.

1. Gritsaev S.V. Myelodysplastic syndromes. In: Rukavitsyn O.A., ed. Haematology. Moscow: GEOTAR-Media; 2015: 300–33. (in Russian)

2. Rollison D.E., Howlader N., Smith M.T., Strom S.S., Merritt W.D., Ries L.A., et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood. 2008; 112(1): 45–52. doi: 10.1182/blood-2008-01-134858.

3. Semochkin S.V., Tolstykh T.N., Rumyantsev A.G. Myelodysplastic syndromes: therapeutic problems and decisions (review). Oncohematology. Russian Journal (Onkogematologiya). 2012; 2: 57–66. (in Russian)

4. Sekeres M.A. Epidemiology, natural history, and practice patterns of patients with myelodysplastic syndromes in 2010. J. Natl. Compr. Canc. Netw. 2011; 9(1): 57–63.

5. Maynadie M., Verret C., Moskovtchenko P., Mugneret F., Petrella T., Caillot D., Carli P.M. Epidemiological characteristics of myelodysplastic syndrome in a well-defined French population. Br. J. Cancer. 1996; 74(2): 288–90.

6. Radlund A., Thiede T., Hansen S., Carlsson M., Engquist L. Incidence of myelodysplastic syndromes in a Swedish population. Eur. J. Haematol. 1995; 54(3): 153–6.

7. Gore S.D., Fenaux P., Santini V., Bennett J.M., Silverman L.R., Seymour J.F., et al. A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial. Haematologica. 2013; 98(7): 1067–72. doi: 10.3324/haematol.2012.074831.

8. Garcia-Manero G. Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management. Am. J. Hematol. 2012; 87(7): 692– 701. doi:10.1002/agh.23264.

9. Steensma D.P., Tefferi A. Risk-based management of myelodysplastic syndrome. Oncology (Willston Park). 2007; 21(1): 43–54.

10. Savchenko V.G., Parovichnikova E.N., Kokhno A.V., Semochkin S.V., Afanasiev B.V., Morozova E.V., et al. National clinical guidelines for the diagnosis and treatment of myelodysplastic syndromes adults. Hematology and Transfusiology. Russian journal (Gematologiya i transfusiologiya). 2016; 61(1, Suppl. 4): 1–32. (in Russian)

11. Fenaux P., Mufti G.J., Hellstrom-Lindberg E., Santini V., Finelli C., Giagounidis A., et al.; International Vidaza High-Risk MDS Survival Study Group. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomized, open-label, phase III study. Lancet. Oncol. 2009; 10(3): 223–32. doi:10.1016/S1470-2045(09)70003-8.

12. Silverman L.R., Demakos E.P., Peterson B.L., Kornblith A.B., Holland J.C., Odchimar-Reissig R., et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J. Clin. Oncol. 2002; 20(10): 2429–40. doi:10.1200/JCO.2002.04.117.

13. Silverman L.R., McKenzie D.R., Peterson B.L., Holland J.F., Backstrom J.T., Beach C.L., et al.; Cancer and Leukemia Group B. Further analysis of trials with azacitidine of patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J. Clin. Oncol. 2006; 24(24): 3895–903. doi:10.1200/JCO.2005.05.4346.

14. Cheson B.D., Bennett J.M., Kopecky K.J., Buchner T., Willman C.L., Estey E.H., et al.; International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J. Clin. Oncol. 2003; 21(24): 4642–9. doi:10.1200/JCO.2003.04.036.

15. Baranova O.Yu. Acute leukemia and myelodysplastic syndromes.. Clinical Oncohematology. Basic research and clinical practice. Russian Journal (Klinicheskaya onkogematologiya. Fundamentalnye issledovaniya i klinicheskaya praktika). 2012; 5(4): 392–6. (in Russian)

16. Semochkin S.V., Tolstykh T.N., Ivanova V.L., Lunin V.V., Pochtar M.E., Tumanova E.L., et al. Azacitidine in the treatment of MDS: clinical observation and literature review. Clinical Oncohematology. Basic research and clinical practice. Russian Journal (Klinicheskaya onkogematologiya. Fundamentalnye issledovaniya i klinicheskaya praktika). 2012; 5(3): 234–8. (in Russian)

17. NCCN Clinical Practice Guidelines in Oncology. Myelodysplastic Syndromes. Available at: https://www.nccn.org/professionals/physician_gls/pdf/mds.pdf (accessed 07 Dec 2016).

18. Vardiman J.W., Thiele J., Arber D.A., Brunning R.D., Borowitz M.J., Porwit A., et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2008; 114(5): 937–51. doi: 10.1182/blood-2009-03-209262.

19. Arber D.A., Orazi A., Hasserjian R., Thiele J., Borowitz M.J., Le Beau M.M., et al. The 2016 revision to the WHO classification of myeloid neoplasms and acute leukemia. Blood. 2016; 127(20): 2391–405. doi:10.1182/blood-2016-03-643544.

20. Greenberg P., Cox C., LeBeau M.M., Fenaux P., Morel P., Sanz G., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997; 89(6): 2079–88.